+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Temozolomide Market Outlook 2026-2034: Market Size, Share and Growth Analysis- Product Image
Temozolomide Market Outlook 2026-2034: Market Size, Share and Growth Analysis- Product Image
Sale

Temozolomide Market Outlook 2026-2034: Market Size, Share and Growth Analysis

  • PDF Icon

    Report

  • 160 Pages
  • October 2026
  • Region: Global
  • OG Analysis
  • ID: 6242892
UP TO OFF until Jan 01st 2027
Description Jump to:
The Temozolomide Market is estimated at US$1.6 billion in 2026 and is projected to grow at a CAGR of 7.4% to reach US$2.8 billion by 2034.

Market Overview

The Temozolomide Market covers oncology drug products and specialty treatment pathways centered on temozolomide use for brain tumor management and related chemotherapy regimens.

Its value chain includes active pharmaceutical ingredient suppliers, formulation manufacturers, oncology distributors, hospitals, specialty pharmacies, clinicians, and payer systems. Core applications include glioblastoma treatment, brain tumor care, combination chemotherapy protocols, hospital oncology use, and specialty outpatient cancer therapy.

Key Companies Analysed

  • Merck & Co
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical
  • Dr. Reddy’s Laboratories
  • Aurobindo Pharma
  • Cipla
  • Lupin
  • Torrent Pharmaceuticals
  • Amneal Pharmaceuticals
  • Sandoz
  • Apotex
  • Zydus Lifesciences
  • Hikma Pharmaceuticals
  • Alkem Laboratories
  • Viatris
  • Accord Healthcare
  • Fresenius Kabi
  • Baxter
  • Pfizer
  • Novartis

Geographic Coverage

  • North America - Market data and outlook to 2034
    • United States
    • Canada
    • Mexico

  • Europe - Market data and outlook to 2034
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Netherlands
    • Switzerland
    • Poland
    • Sweden
    • Russia

  • Asia-Pacific - Market data and outlook to 2034
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Vietnam

  • Middle East and Africa - Market data and outlook to 2034
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Egypt

  • South and Central America - Market data and outlook to 2034
    • Brazil
    • Argentina
    • Chile
    • Peru

*We can include data and analysis of additional countries on demand.

Report Delivery and Support

  • Updated PDF report and an MS Excel workbook containing market tables and figures.
  • 7-day post-sale analyst support for clarifications and in-scope supplementary data.
  • Complimentary report update covering the latest available data and relevant market developments.

This product will be delivered within 1-3 business days.

Table of Contents

1. Contents and Report Guide
1.1. List of Tables
1.2. List of Figures
2. Global Temozolomide Market Overview
2.1. Temozolomide Market Scope and Definitions
2.2. Research Methodology and Forecast Assumptions
2.3. Value Chain and Relevant Adjacent Markets
3. Temozolomide Market Dynamics
3.1. Demand Drivers
3.2. Constraints and Adoption Barriers
3.3. Technology and Commercial Trends
3.4. Regulatory and Supply-Chain Considerations
4. Temozolomide Market Strategic Analysis
4.1. Competitive Structure
4.2. Pricing and Purchasing Factors
4.3. Customer Requirements and Opportunity Assessment
5. Global Temozolomide Market Size, Share and Forecast, 2025-2034
5.1. Revenue Outlook, 2025-2034 (US$ billion)
6. North America Temozolomide Market Outlook to 2034
6.1. North America Market Snapshot
6.2. North America Outlook By Country
6.2.1. United States
6.2.2. Canada
6.2.3. Mexico
7. Europe Temozolomide Market Outlook to 2034
7.1. Europe Market Snapshot
7.2. Europe Outlook By Country
7.2.1. Germany
7.2.2. United Kingdom
7.2.3. France
7.2.4. Italy
7.2.5. Spain
7.2.6. Netherlands
7.2.7. Switzerland
7.2.8. Poland
7.2.9. Sweden
7.2.10. Russia
8. Asia-Pacific Temozolomide Market Outlook to 2034
8.1. Asia-Pacific Market Snapshot
8.2. Asia-Pacific Outlook By Country
8.2.1. China
8.2.2. Japan
8.2.3. India
8.2.4. South Korea
8.2.5. Australia
8.2.6. Indonesia
8.2.7. Malaysia
8.2.8. Vietnam
9. Middle East and Africa Temozolomide Market Outlook to 2034
9.1. Middle East and Africa Market Snapshot
9.2. Middle East and Africa Outlook By Country
9.2.1. Saudi Arabia
9.2.2. South Africa
9.2.3. Iran
9.2.4. United Arab Emirates
9.2.5. Egypt
10. South and Central America Temozolomide Market Outlook to 2034
10.1. South and Central America Market Snapshot
10.2. South and Central America Outlook By Country
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Chile
10.2.4. Peru
11. Temozolomide Market Competitive Landscape
11.1. Market Participants and Strategic Positioning
11.2. Company Profiles: Product Portfolios, Positioning and Strategies
11.2.1. Merck & Co
11.2.2. Teva Pharmaceutical Industries
11.2.3. Sun Pharmaceutical
11.2.4. Dr. Reddy's Laboratories
11.2.5. Aurobindo Pharma
11.2.6. Cipla
11.2.7. Lupin
11.2.8. Torrent Pharmaceuticals
11.2.9. Amneal Pharmaceuticals
11.2.10. Sandoz
11.2.11. Apotex
11.2.12. Zydus Lifesciences
11.2.13. Hikma Pharmaceuticals
11.2.14. Alkem Laboratories
11.2.15. Viatris
11.2.16. Accord Healthcare
11.2.17. Fresenius Kabi
11.2.18. Baxter
11.2.19. Pfizer
11.2.20. Novartis
12. Appendix
12.1. Definitions and Abbreviations
12.2. Data Sources and Methodology
12.3. Publisher Information

Companies Mentioned

  • Merck & Co
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical
  • Dr. Reddy’s Laboratories
  • Aurobindo Pharma
  • Cipla
  • Lupin
  • Torrent Pharmaceuticals
  • Amneal Pharmaceuticals
  • Sandoz
  • Apotex
  • Zydus Lifesciences
  • Hikma Pharmaceuticals
  • Alkem Laboratories
  • Viatris
  • Accord Healthcare
  • Fresenius Kabi
  • Baxter
  • Pfizer
  • Novartis

Table Information

Report AttributeDetails
No. of Pages160
PublishedOctober 2026
Forecast Period2026 - 2034
Estimated Market Value ( USD ) in 2026 $ 1.6 Billion
Forecasted Market Value ( USD ) by 2034 $ 2.8 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Temozolomide (CAS 85622-93-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Temozolomide (CAS 85622-93-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies. Cancer Sensitizing Agents for Chemotherapy Volume 15 - Product Image

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies. Cancer Sensitizing Agents for Chemotherapy Volume 15

  • Book
Ewing Sarcoma - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Ewing Sarcoma - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 140 Pages
  • Global
From
New Strategies Targeting Cancer Metabolism. Anticancer Drugs, Synthetic Analogues and Antitumor Agents - Product Image

New Strategies Targeting Cancer Metabolism. Anticancer Drugs, Synthetic Analogues and Antitumor Agents

  • Book
Alkylating Agents Market Report 2026 - Product Image

Alkylating Agents Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Temozolomide Market

Temozolomide is an alkylating agent used in the treatment of certain types of cancer, most notably glioblastoma multiforme. It is a prodrug, which is converted in the body to its active form, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC). Temozolomide is used in combination with radiation therapy to treat newly diagnosed glioblastoma multiforme, and as a single agent to treat recurrent glioblastoma multiforme. It is also used to treat anaplastic astrocytoma, a type of brain tumor. Temozolomide is a generic drug, and is available in many countries. It is marketed by several companies, including Merck, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.